A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, composed of a combination of an anti-VEGF agent, and a pyrrolo[1,2-a]pyrazine derivative represented by a general formula (I):in the formula, R1 and R2 are simultaneously or individually each a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkyl group, a lower alkoxy group or a nitro group, and R3 is a hydrogen atom, a halogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof.
